QSAM Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 15:56):

Stats
Today's Volume	13 392.00
Average Volume	8 350.00
Market Cap	36.68M
EPS	$0 ( 2024-03-12 )
Next earnings date	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.88
ATR14	$0.0610 (0.74%)

Insider Trading

Date	Person	Action	Amount	type
2023-01-15	Checkmate Strategic Capital 2, Llc	Buy	50 000	Warrants
2023-12-19	Checkmate Strategic Capital 2, Llc	Sell	50 000	Warrants
2024-02-06	Checkmate Strategic Capital 2, Llc	Sell	156	Series B Convertible Preferred Stock
2024-02-06	Baum Douglas R	Buy	1 302	Common Stock
2024-02-06	Baum Douglas R	Sell	0	Series B Convertible Preferred Stock

INSIDER POWER
67.85
Last 80 transactions
Buy: 23 187 033 \| Sell: 6 676 587

QSAM Biosciences, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

QSAM Biosciences, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.440

Q4	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.130

Q3	2023
Revenue:	$0
Gross Profit:	$-275 273 (0.00 %)
EPS:	$-0.340

Q2	2023
Revenue:	$0
Gross Profit:	$-274 066 (0.00 %)
EPS:	$-0.420

Financial Reports:

No articles found.

QSAM Biosciences, Inc.

QSAM Biosciences, Inc. engages in developing various nuclear medicines for the treatment of cancer and related diseases. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was incorporated in 2004 and is headquartered in Austin, Texas.